Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Oppenheimer Downgrades 8×8 to Perform

Oppenheimer Downgrades 8×8 to Perform

Oppenheimer analyst Timothy Horan downgrades 8×8 (NYSE:EGHT) from Outperform to Perform.

byBenzinga Newsdesk

August 5, 2022

1 minute read

Oppenheimer analyst Timothy Horan downgrades 8×8 (NYSE:EGHT) from Outperform to Perform.

Analyst Ratings

Where Xenon Pharmaceuticals Stands With Analysts

By Benzinga Insights

November 28, 11:04 AM

Over the past 3 months, 4 analysts have published their opinion on Xenon Pharmaceuticals (NASDAQ:XENE) stock. These analysts…

XENE

Piper Sandler Downgrades Thoughtworks Holding to Neutral, Lowers Price Target to $9.5

By Benzinga Newsdesk

November 15, 4:54 AM

Piper Sandler analyst Arvind Ramnani downgrades Thoughtworks Holding (NASDAQ:TWKS) from Overweight to Neutral and lowers the price target from $14 to $9.5.

TWKS

Analyst Ratings

Unveiling 27 Analyst Insights On DoorDash

By Benzinga Insights

April 29, 2:00 PM

Across the recent three months, 27 analysts have shared their insights on DoorDash (NASDAQ:DASH), expressing a variety of…

DASH

Argenx Announces U.S. FDA Acceptance Of Biologics License Application For Subcutaneous Efgartigimod In Generalized Myasthenia Gravis With Priority Review; PDUFA Date Is March 20, 2023

By Benzinga Newsdesk

November 22, 2:05 AM

- Prescription Drug User Fee Act (PDUFA) target action date is March 20, 2023 - Submission based on positive results from the Phase 3 bridging study demonstrating noninferior total IgG reduction at day

ARGX

Oppenheimer Downgrades 8×8 to Perform

Related Posts

Where Xenon Pharmaceuticals Stands With Analysts

Piper Sandler Downgrades Thoughtworks Holding to Neutral, Lowers Price Target to $9.5

Unveiling 27 Analyst Insights On DoorDash

Argenx Announces U.S. FDA Acceptance Of Biologics License Application For Subcutaneous Efgartigimod In Generalized Myasthenia Gravis With Priority Review; PDUFA Date Is March 20, 2023